What's Happening?
VitriVax, Inc. has been awarded a $9.9 million grant from the Gates Foundation to support the scale-up of its Atomic Layering Thermostable Antigen and Adjuvant (ALTA) technology. The funding will enable
Phase 1-ready GMP manufacturing and advance the platform for clinical trials. VitriVax will collaborate with a Contract Development and Manufacturing Organization (CDMO) to prepare for early-phase clinical production, focusing on innovative vaccine technologies that enhance global public health.
Why It's Important?
The grant from the Gates Foundation underscores the potential of VitriVax's ALTA technology to revolutionize vaccine manufacturing, offering thermostable, single-shot vaccines across various indications. This funding will accelerate the transition from lab-scale innovation to clinical production, enhancing vaccine accessibility and supply resilience. The development of ALTA-enabled vaccines could significantly impact global health, providing effective immunization solutions in diverse settings.
What's Next?
VitriVax will focus on scaling up ALTA technology for Phase 1 clinical trials, working with a CDMO to ensure GMP-compliant manufacturing. The company aims to de-risk early clinical manufacturing and accelerate timelines for first-in-human studies, paving the way for broader access to next-generation vaccines.
Beyond the Headlines
The ALTA technology represents a breakthrough in vaccine formulation, enabling the co-formulation of multiple antigens and adjuvants in a single injection. This innovation aligns with global health priorities, emphasizing the importance of scalable and reliable vaccine production to address public health challenges.
